NVS

Novartis AG ADR

160.79

Oct 30 • 3:59 PM ET -0.31 (-0.19%)

163.00

Aftermarket • 7:44 PM ET +2.21 (1.37%)

Healthcare Drug Manufacturers - General Switzerland Mega NYSE

Peers: AZN MRK PFE SNY ABBV BMY GSK JNJ AMGN LLY

| Held by: DFIV DFAI DFIC AVDE DIHP DFAX FENI PPH FVD IDVO

Scroll to Statements

Index	-
Market Cap	294.33B
Enterprise Value	334.01B
Income	10.04B
Sales	55.35B
Book/sh	19.71
Cash/sh	4.90
Dividend Est.	4.34 (2.70%)
Dividend TTM	4.74 (2.95%)
Dividend Ex-Date	Mar 11, 2026
Dividend Gr. 3/5Y	10.71% 8.17%
Payout	42.50%
Employees	75267
IPO	Nov 07, 1996

P/E	30.71
Forward P/E	16.31
PEG	2.58
P/S	5.32
P/B	8.16
P/C	32.79
P/FCF	18.81
EV/EBITDA	15.10
EV/Sales	6.03
Quick Ratio	0.70
Current Ratio	0.88
Debt/Eq	1.30
LT Debt/Eq	1.03
Option/Short	Yes / Yes

EPS (ttm)	5.24
EPS next Y	9.86
EPS next Q	2.24
EPS this Y	-1.29%
EPS next Y	11.18%
EPS next 5Y	6.33%
EPS past 3/5Y	31.40% 15.24%
Sales past 3/5Y	9.03% 2.29%
EPS Y/Y TTM	-28.72%
Sales Y/Y TTM	1.64%
EPS Q/Q	-68.95%
Sales Q/Q	4.03%
Earnings	Oct 27 BMO
EPS/Sales Surpr.	8.32% -0.07%

Insider Own	0.01%
Insider Trans	0.00%
Inst Own	7.44%
Inst Trans	0.06%
ROA	8.95%
ROE	24.62%
ROIC	13.28%
Gross Margin	74.30%
Oper. Margin	30.47%
Profit Margin	18.14%
SMA20	7.20%
SMA50	8.35%
SMA200	5.92%
Trades

Shs Outstand	1.89B
Shs Float	1.83B
Short Float	0.31%
Short Ratio	2.76
Short Interest	5.59M
52W High	170.46 -5.67%
52W Low	121.98 31.82%
Volatility	1.83% 1.57%
ATR (14)	3.27
RSI (14)	68.76
Beta	0.43
Rel Volume	1.56
Avg Volume	2.02M
Volume	3,152,901

Perf Week	6.40%
Perf Month	14.00%
Perf Quarter	4.63%
Perf Half Y	9.70%
Perf YTD	16.62%
Perf Year	31.14%
Perf 3Y	71.49%
Perf 5Y	105.32%
Perf 10Y	166.92%
Recom	2.00
Target Price	158.20
Prev Close	161.10
Price	160.79
Change %	-0.19%

Consensus

Buy

Avg. Price Target

$158.20

Implied Upside

-1.6%

Analysts12incl. previous ratings

Rating Distribution5 Buy · 5 Hold · 2 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 30, 2026	Downgrade	DDeutsche Bank	Hold → Sell
Sep 10, 2026	Upgrade	HHSBC Securities	Reduce → Hold
Sep 09, 2026	Initiated	RRBC Capital Mkts	Sector Perform
Sep 09, 2026	Downgrade	DDeutsche Bank	Buy → Hold
Mar 11, 2026	Upgrade	AArgus	Hold → Buy	$180	+11.9%
Jan 27, 2026	Initiated	CCitigroup	Buy
Jan 06, 2026	Upgrade	BBarclays	Underweight → Equal Weight
Dec 08, 2025	Upgrade	JJP Morgan	Neutral → Overweight
Dec 03, 2025	Upgrade	MMorgan Stanley	Equal-Weight → Overweight
Nov 25, 2025	Upgrade	BBofA Securities	Neutral → Buy
Sep 12, 2025	Downgrade	GGoldman	Neutral → Sell	$118	-26.6%
Aug 08, 2025	Upgrade	MMorgan Stanley	Underweight → Equal-Weight	$123	-23.5%
Feb 13, 2025	Downgrade	UUBS	Buy → Neutral
Feb 12, 2025	Initiated	MMorgan Stanley	Underweight
Feb 04, 2025	Upgrade	DDeutsche Bank	Hold → Buy
Dec 04, 2024	Downgrade	HHSBC Securities	Hold → Reduce
Sep 11, 2024	Downgrade	BBofA Securities	Buy → Neutral	$135 → $130	-19.1%
Sep 05, 2024	Downgrade	GGoldman	Buy → Neutral
Sep 03, 2024	Downgrade	JJefferies	Buy → Hold
Jul 19, 2024	Downgrade	DDeutsche Bank	Buy → Hold

Oct-30-26 08:43AM	AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock (Barrons.com)
08:16AM	Eli Lillys tirzepatide outperforms big pharma companies in Q3 (Pharmaceutical Technology)
07:50AM	Earnings roundup: Lillys unwavering momentum, Novartis rebound and GSKs waiting game (BioPharma Dive)
Oct-28-26 09:27AM	Lilly shuffles business structure; Novartis writes off part of Avidity deal (BioPharma Dive)
Oct-27-26 10:45AM	Novartis CEO says company must stay 'courageous' to pursue breakthroughs (CNBC TV)
09:05AM	Loading…
09:05AM	Novartis raises 2026 profit outlook as drug sales offset $1.9 billion impairment (Proactive)
07:31AM	Novartis Raises 2026 Profit Forecast After Q3 Sales Rise 4% to $14.52 Billion (InvestorsHub)
06:22AM	Coca-Cola, Boeing, Celestica, Whirlpool, and More Stocks That Explain Today's Market (Barrons.com)
04:43AM	European shares fall as HSBC slump and energy fears offset AI glow (Investing.com)
02:53AM	Novartis raises profit outlook after strong Q3 sales growth; shares rise (Investing.com)
02:20AM	Novartis: Q3 Earnings Snapshot (Associated Press)
Oct-26-26 03:33PM	Top Analyst Reports for Intel, Novartis & Itau Unibanco (Zacks)
07:52AM	Novartis Reports Lower Relapse Rates and No Hy's Law Cases in Phase 3 Remibrutinib MS Trials (InvestorsHub)
05:32AM	Novartis MS drug remibrutinib cuts relapses, no liver safety signal in trials (Investing.com)
Oct-24-26 05:36AM	AI Bubble Fears Trigger a Surprising Shift to Swiss Stocks (BeInCrypto)
04:37AM	Loading…
04:37AM	Swiss stocks outperform Europe as investors retreat from AI trade - Bloomberg (Investing.com)
Oct-22-26 01:08PM	The Week Ahead: Wall Street Awaits October Fed Decision (Schaeffer's Research)
Oct-20-26 06:03PM	Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors (Exec Edge)
Oct-19-26 06:18AM	Novartis Discontinues Mid-Stage Fabhalta Trial in Lupus Nephritis for Strategic Reasons (InvestorsHub)
Oct-16-26 05:54PM	Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback (Stocktwits)
05:03PM	Novartis Scraps Another Drug Study. Why the Stock Is Holding Steady. (Barrons.com)
Oct-11-26 09:22PM	SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH (Stocktwits)
Oct-09-26 09:12PM	Stocktwits Biotech Dealmaker Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights (Stocktwits)
Oct-08-26 11:43AM	Argenx Stock Sinks as Scrapped Vyvgart Trial Erases $3.5 Billion Opportunity (Barrons.com)
Oct-07-26 06:12AM	AI companies run virtual drug trials, aim to improve success of human studies (Reuters)
Oct-05-26 08:38AM	GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition (Barrons.com)
Oct-02-26 08:13PM	Stocktwits Biotech Dealmaker Novartis, Sanofi And Novo Sign Weeks Biggest Deals (Stocktwits)
10:16AM	Novartis wagers almost $8B on a Chinese biotechs RNA drugs (BioPharma Dive)
09:50AM	Novartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion (Quartz)
09:40AM	Novartis licenses Abogen mRNA autoimmune drug in $7.8B deal (Quartz)
06:24AM	Loading…
06:24AM	Novartis Signs RNA Therapy Licensing Deal With China's Abogen Worth Up to $7.8 Billion (InvestorsHub)
Oct-01-26 08:09AM	Deutsche Bank lists Top European Stock picks for the next twelve months (Investing.com)
Sep-25-26 09:02PM	Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines (Stocktwits)
08:00AM	Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset (FinanceWire)
Sep-24-26 01:06PM	Roche targets Novartis on IgAN market after Phase III win (Clinical Trials Arena)
12:32PM	MSDs DME drug could challenge anti-VEGF reign, late-stage study suggests (Clinical Trials Arena)
Sep-23-26 02:06PM	Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof (GuruFocus.com)
12:21PM	Roche, Ionis RNA drug scores in kidney disease study (BioPharma Dive)
10:52AM	European big pharma unites amid ringing alarm bells of continents dominance (Clinical Trials Arena)
06:18AM	BoomRay and Novartis sign $900m deal for radioligand therapy (Pharmaceutical Technology)
06:14AM	BoomRay and Novartis Pharma sign $900m deal for radioligand therapy (Pharmaceutical Business Review)
Sep-22-26 03:26PM	AstraZeneca and GSK warn Europes drug industry is at risk (The Telegraph)
Sep-21-26 11:55AM	Novo Nordisk shares plunge over 7% as new targets fail to reassure investors (Proactive)
Sep-19-26 10:30PM	What does the EU have that the U.S. does not? (Investing.com)
Sep-17-26 10:26AM	Amgen Stock Fell 10% in a Day on a Drug It Doesnt Own. Is It Time to Buy AMGN? (TIKR)
Sep-16-26 12:33PM	Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal Is Betting on It. (Barrons.com)
12:26PM	Novartis to pay $125M for blood-brain barrier crossing platform (BioPharma Dive)
10:37AM	AstraZeneca shares oversold after trial flops and merger talk, says UBS (Proactive)
Sep-15-26 07:40PM	LEGNs New CEO From Novartis Paves Way For Buyout Speculation (Stocktwits)
01:13PM	FDA clears first generic radioligand drug; Sionna turns to layoffs (BioPharma Dive)
Sep-11-26 03:54PM	Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning (GuruFocus.com)
01:48PM	MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near (Stocktwits)
09:08AM	Novartis investors turn spotlight on M&A after trial setbacks (Reuters)
07:22AM	This week in charts: RAs insatiable appetite, Novartis big slide and a reverse merger spree (BioPharma Dive)
Sep-10-26 02:26PM	Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge (GuruFocus.com)
01:46PM	NVS Stock On Track For Worst Week In Over 7 Years After Two Trial Failures In A Week Investor Reportedly Seeks Board Overhaul (Stocktwits)
09:41AM	Exclusive-Major Novartis shareholder calls for board shake-up after drug trial setbacks (Reuters)
07:07AM	Artisan Partners calls for Novartis board changes amid trial, acquisition failures (Investing.com)
05:13AM	HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review (Investing.com)
Sep-09-26 11:41AM	Wall Street Weighs Impact On DYN Stock Post Novartis Phase 3 Failure RBC Says These Key Differences Could Lead To Better Outcomes (Stocktwits)
09:51AM	Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls (The Fly)
Sep-08-26 04:09PM	NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week DYN, SRPT Slip In Sympathy (Stocktwits) -13.93%
12:59PM	Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails (GuruFocus.com)
12:46PM	European shares muted as oil rally fuels caution; Novartis tumbles (Reuters)
11:04AM	Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial (Proactive)
10:33AM	Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday (Investopedia)
10:25AM	Novartis and Boston Scientific Slide, Intel Price Hikes \| Stock Movers (Bloomberg)
09:57AM	Healthcare stocks tumble (MarketWatch)
09:10AM	Novartis Stock Falls 12% on Its Third Trial Setback In a Week (GuruFocus.com)
08:57AM	Novartis Is Having a Very Bad September-and More Pain Could Be on the Way (Barrons.com)
08:56AM	Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly (Quartz)
08:16AM	5 Things to Know Before the Stock Market Opens on Tuesday (Investopedia)
07:34AM	Novartis del-desiran drug trial fails, stock drops 9% (Quartz)
07:28AM	BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts (Investing.com)
07:26AM	Novartis twin drug setbacks pile pressure on pipeline and CEO (Reuters)
06:56AM	Beneath the surface, the next market leaders are getting ready to break out, says Morgan Stanley (MarketWatch)
06:54AM	Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint (InvestorsHub)
06:52AM	Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade (InvestorsHub)
06:50AM	Novartis $12bn Avidity bet falters on late-stage del-desiran flop (Clinical Trials Arena)
06:26AM	Novartis DM1 Drug Misses Primary Endpoint in Phase III Trial (InvestorsHub)
05:39AM	Novartis India acquires Pfizer brands for $132m (Pharmaceutical Business Review)
04:15AM	Why the Dow is being dragged down by a Swiss company's bad news (MarketWatch)
Sep-07-26 05:46PM	Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar (GuruFocus.com)
01:50PM	Novartis Falls 1.9% as Pelacarsen Failure Erases CHF4.9 Billion (GuruFocus.com)
12:33PM	European shares subdued as surging crude sharpens focus on ECB rate path (Reuters)
10:44AM	Novartis Just Lost a Potential $6 Billion Drug Opportunity (GuruFocus.com)
06:35AM	Novartis Shares Fall After Pelacarsen Misses Primary Goal in Late-Stage Heart Trial (InvestorsHub)
06:00AM	Weight loss is just the beginning of GLP-1's: Novo Nordisk CEO (Yahoo Finance Video)
Sep-05-26 08:51AM	Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines (BioPharma Dive)
Sep-04-26 06:52PM	NVS, IONS, AMGN Stocks Drop After-Hours Whats Driving The Selloff? (Stocktwits) -13.93%
09:10AM	Novartis and Bristol Myers are halting cell therapy trials for autoimmune diseases after patient deaths (Quartz)
Sep-03-26 05:37AM	Novartis signs drug delivery deal with Alteogen (Pharmaceutical Technology)
05:37AM	Novartis signs $3.2bn drug delivery deal with Alteogen (Pharmaceutical Technology)
05:37AM	Novartis signs deal with Alteogen for drug delivery (Pharmaceutical Business Review)
Sep-02-26 12:02PM	Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery (GuruFocus.com)
08:33AM	Novartis stock rises after MS drug remibrutinib trial results (Quartz)
08:33AM	Novartis stock surged after its oral multiple sclerosis pill passed two late-stage trials (Quartz)
08:32AM	Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
08:00AM	Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials (Proactive)
Sep-01-26 03:27PM	TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis (Stocktwits) +6.04%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Bulto Carulla Victor	Officer	Oct 28 '26	Proposed Sale	155.53	6,000	933,180	Oct 28 10:46 AM
Bulto Carulla Victor	Officer	Apr 30 '26	Proposed Sale	148.10	6,800	1,007,093	Apr 30 12:05 PM
Marshall Fiona	Officer	Feb 12 '26	Proposed Sale	161.35	30,743	4,960,277	Feb 12 02:43 PM
Bulto Carulla Victor	Officer	Feb 09 '26	Proposed Sale	156.21	7,500	1,171,576	Feb 09 11:49 AM

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Chief Executive OfficerDr. Vasant Narasimhan M.D.

President of USMr. Victor Bulto

President of InternationalDr. Patrick Horber M.D.

Chief Financial OfficerMr. Mukul Mehta

President of OperationsDr. Steffen Lang Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVS

Novartis AG ADR

Upgrade your Finviz experience